Northwest BiotherapeuticsNWBO
13F holders, Q1 2026 (March 31)8holders +1
2new positions
1sold out
$0.20avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, up 1 from Q4 2025. 2 opened new positions and 1 sold out. The largest holders were Kelleher Financial Advisors ($41K), VSM Wealth Advisory, LLC ($17K) and Opus Capital Group, LLC ($12K).
- Company
- Northwest Biotherapeutics
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $41K |
| Exits | 1 | $2K |
All 13F filers, Q4 2025 → Q1 2026: 211,320 shares bought and 12,270 shares sold, net +199,050 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Kelleher Financial Advisors | 0.01% | New | 200,000 | $41K |
| VSM Wealth Advisory, LLC | 0.01% | No change | 80,574 | $17K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $12K |
| Ethos Financial Group, LLC | 0.00% | Add +37.8% | 39,070 | $8K |
| Williams Jones Wealth Management, LLC. | 0.00% | Reduce -7.4% | 25,000 | $5K |
| McIlrath & Eck, LLC | 0.00% | New | 600 | $124 |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.